Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 6.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 347,610 shares of the company’s stock after selling 22,378 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Atossa Therapeutics were worth $528,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Intech Investment Management LLC purchased a new stake in Atossa Therapeutics during the 3rd quarter worth approximately $29,000. XTX Topco Ltd bought a new stake in shares of Atossa Therapeutics in the second quarter worth $29,000. SG Americas Securities LLC raised its holdings in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares in the last quarter. Rhumbline Advisers bought a new position in Atossa Therapeutics during the 2nd quarter valued at $161,000. Finally, Renaissance Technologies LLC grew its holdings in Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after acquiring an additional 164,540 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

NASDAQ ATOS opened at $0.99 on Thursday. The firm has a market capitalization of $124.54 million, a PE ratio of -4.50 and a beta of 1.21. Atossa Therapeutics, Inc. has a one year low of $0.70 and a one year high of $2.31. The company has a 50-day simple moving average of $1.33 and a 200-day simple moving average of $1.32.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ATOS. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Thursday, December 12th. StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th. Finally, Ascendiant Capital Markets boosted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.